Intraocular inflammation with intravitreal bevacizumab (Avastin)

Intraocular inflammation with intravitreal bevacizumab (Avastin)

Along with the efficacy, safety and tolerability is a key issue with the use of anti-VEGF agents, 2 3 as ranibizumab (Lucentis) is now the standard of care for neovascular age-related macular degeneration according to NICE UK recommendations. 4 5 However, the spectrum of off-label therapeutic indica...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of ophthalmology 2010-04, Vol.94 (4), p.525-525
Hauptverfasser: Raja, Muhammad S, Goldsmith, Craig, Burton, Benjamin J L
Format: Artikel
Sprache:eng
Schlagworte:
Angiogenesis Inhibitors - adverse effects
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal, Humanized
Bevacizumab
Choroidal Neovascularization - drug therapy
Female
Humans
Inflammation
Intravitreal Injections
Macular degeneration
Neovascularisation
Ranibizumab
Uveitis - chemically induced
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Along with the efficacy, safety and tolerability is a key issue with the use of anti-VEGF agents, 2 3 as ranibizumab (Lucentis) is now the standard of care for neovascular age-related macular degeneration according to NICE UK recommendations. 4 5 However, the spectrum of off-label therapeutic indications for anti-VEGF agents simply continues to grow, especially with the use of Avastin.
ISSN:0007-1161
1468-2079
DOI:10.1136/bjo.2009.166033